CTLA4 and neoplasm: In these conditions, treatment with monoclonal antibodies against immune checkpoint molecules, such as programmed cell death protein-1 receptor (PD-1) and/or cytotoxic T lymphocyte-associated protein 4 (CTLA-4), can result in enhanced cytotoxic activation of tumor antigen-specific T cells and in eradication of tumor lesions.